Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Editorial acerca de “Fístula pancreática posduodenopancreatectomía. Pancreatogastrostomía vs. pancreatoyeyunostomía”

Pancreatic fistula is the most dreaded complication after pancreaticoduodenectomy due to its morbidity and mortality. Multiple procedures to reduce the incidence of this complication have been described: a- Systematic inhibition of pancreatic enzyme secretion using octapeptide in the postoperative period; bUse of biological fibrin-based adhesive to cover and reinforce the anastomosis; c- Use of omentum flap to wrap the pancreatic anastomosis with the jejunum; dAnastomosis with Wirsung duct stenting; e- Telescopic anastomosis; f- Duct-to-mucosa anastomosis (the most commonly used technique today); g- Use of magnification, etc